Novo's CagriSema fails to match Lilly's Zepbound in key obesity trial FirstWord Pharma Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Novo Nordisk's cagrilintide shows promise in Phase 3 trial Alan Nafiev posted on the topic LinkedIn Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Topline data from REDEFINE 1 found CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. https: t.co JA9E3FpCsN #ObesityManagement #